Johnson & Johnson Kick-Starts Suzhou Production
This article was originally published in PharmAsia News
Johnson & Johnson Medical has commenced operation at its Suzhou Industrial Park, starting off with orthopedic implants, which have been experiencing the fastest growth in the firm's portfolio. The first DePuy factory will make products related to artificial joint replacement and trauma care to fulfill 10-20 percent of the company's global output. With other localized products coming online, the Suzhou base is set to become J&J Medical's largest production facility in the next five years. There are plans to introduce minimally invasive surgical devices by the end of this year and cardiology products in 2009. China is experiencing huge domestic demand and growth for orthopedic implants; the market is expected to increase from 500 million yuan in 2007 to 2.1 billion yuan in 2015. (Click here for more - Chinese Language)
You may also be interested in...
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.